Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27775798 | 0.85 | HSD17B1 (0.43) | MEN1KMT2AHSD17B1HSD17B2CYP3A4 | |
| SCHEMBL2092815 | 0.84 | ACHE (0.50) | PTPN5DHODHNPC1RAB9AMEN1 | |
| SCHEMBL29892442 | 0.83 | MEN1 (0.55) | PTPN5DHODHNPC1RAB9AMEN1 | |
| SCHEMBL95329 | 0.80 | ALDH1A1 (0.50) | MEN1KMT2AHSD17B1HSD17B2CYP3A4 | |
| SCHEMBL598796 | 0.80 | ACHE (0.57) | PTPN5DHODHNPC1RAB9AMEN1 | |
| SCHEMBL23003863 | 0.78 | ACHE (0.55) | PTPN5DHODHNPC1RAB9AMEN1 | |
| SCHEMBL13685090 | 0.78 | MAOA (0.48) | DHODHMEN1KMT2AHSD17B1HSD17B2 | |
| SCHEMBL20829312 | 0.78 | DHODH (0.53) | PTPN5DHODHNPC1RAB9ANTSR1 | |
| SCHEMBL29929976 | 0.78 | ACHE (0.55) | PTPN5DHODHNPC1RAB9AMEN1 | |
| SCHEMBL5545442 | 0.78 | ACHE (0.55) | PTPN5DHODHNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491963-B | Method for producing (meth) acrylic composition, coating material containing (meth) acrylic composition, and cured body | 三菱瓦斯化学株式会社 | 2023-04-28 | — | — | CN | disclosed |
| WO-2023069700-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-113710750-B | (meth) acrylic composition, coating material containing same, and cured product | 三菱瓦斯化学株式会社 | 2022-07-12 | — | — | CN | disclosed |
| US-20220145118-A1 | (METH)ACRYLIC COMPOSITION, PAINT AND CURING AGENT COMPRISING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11326073-B1 | (meth)acrylic composition, paint and curing agent comprising same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2022-05-10 | — | — | US | disclosed |
| CN-113710750-A | (meth) acrylic composition, coating material containing same, and cured product | 三菱瓦斯化学株式会社 | 2021-11-26 | — | — | CN | disclosed |
| CN-108603953-B | Light diffusing agent, light diffusing resin composition, and molded article | 三菱瓦斯化学株式会社 | 2021-08-24 | — | — | CN | disclosed |
| CN-109790366-B | (meth) acrylic copolymer, resin composition, molded article thereof, and method for producing molded article | 三菱瓦斯化学株式会社 | 2021-04-27 | — | — | CN | disclosed |
| CN-108822245-B | (meth) acrylic acid-based copolymer | 三菱瓦斯化学株式会社 | 2021-02-12 | — | — | CN | disclosed |
| WO-2020218151-A1 | (METH)ACRYLIC COMPOSITION, PAINT AND CURING AGENT COMPRISING SAME | 三菱瓦斯化学株式会社 | 2020-10-29 | — | — | WO | disclosed |
| US-20060264417-A1 | Succinoylamino lactams as inhibitors of a-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060258638-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-11-16 | — | — | US | disclosed |
| US-7101870-B2 | Succinoylamino lactams as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-6962913-B2 | Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245501-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-03 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-6794381-B1 | BETA -PEPTIDE INHIBITOR PREVENTS NEUROLOGICAL DEPOSITS OF AMYLOID PRECURSOR PROTEIN; ALZHEIMER'S DISEASE AND DOWN'S SYNDROME TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PTPN5 2283/4885DHODH 301/4885NPC1 2404/4885 |
| US-20060264417-A1 | Succinoylamino lactams as inhibitors of a-beta protein production | BACE1, APH1A, APP | PTPN5 4274/4885DHODH 1304/4885NPC1 2769/4885 |
| US-20050245501-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BACE1, APH1A, APP | PTPN5 4274/4885DHODH 1304/4885NPC1 2769/4885 |
| US-20060258638-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BACE1, APH1A, APP | PTPN5 4274/4885DHODH 1304/4885NPC1 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.